CIK 0001520262 · Large accelerated filer
Alkermes plc.
Sign in to watch- Ticker
- ALKS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981007018
- Phone
- 00-353-1-772-8000
- Business address
- CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, Ireland, 00000
- Former names
- ANTLER SCIENCE TWO PLC, Antler Science Two Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,070,874
- in 5 filings, $1.1M under 10b5-1 plans
Net −$1,070,874. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-30 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −26,589 | 161,734 | ||
| 2025-01-30 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −23,542 | 106,758 | ||
| 2025-01-30 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −18,345 | 92,271 | ||
| 2024-12-09 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +12,452 | $20.03 | $249K | 72,182 |
| 2024-12-09 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +12,090 | $19.34 | $234K | 84,272 |
| 2024-12-09 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +12,044 | $24.59 | $296K | 96,316 |
| 2024-12-09 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +12,411 | $26.82 | $333K | 108,727 |
| 2024-12-09 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −61,151 | $32.07 | $2.0M | 47,576 |
| 2024-12-09 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −12,452 | 116,722 | ||
| 2024-12-09 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −12,090 | 188,323 | ||
| 2024-12-09 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −12,044 | 130,300 | ||
| 2024-12-09 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −12,411 | 110,616 | ||
| 2024-12-09 | LAURENCIN CATO T Director | Option exercise 10b5-1 | +2,691 | $22.52 | $61K | 25,704 |
| 2024-12-09 | LAURENCIN CATO T Director | Sale 10b5-1 | −2,691 | $31.85 | $86K | 23,013 |
| 2024-12-09 | LAURENCIN CATO T Director | Option exercise · Non Qualified Stock Option (Right to Buy) 10b5-1 | −2,691 | 16,142 | ||
| 2024-12-08 | LAURENCIN CATO T Director | Option exercise 10b5-1 | +4,163 | 23,971 | ||
| 2024-12-08 | LAURENCIN CATO T Director | Shares withheld for taxes 10b5-1 | −958 | $31.46 | $30K | 23,013 |
| 2024-12-08 | LAURENCIN CATO T Director | Option exercise · Restricted Stock Unit Award 10b5-1 | −4,163 | 0 | ||
| 2024-12-05 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −9,221 | $31.50 | $290K | 59,730 |
| 2024-12-04 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −14,349 | $30.77 | $442K | 68,951 |
Page 20 of 41 · 804 trades